Please use this identifier to cite or link to this item:
https://hdl.handle.net/11499/7577
Title: | The effect of gradual increment in rhG-CSF dose on stem cell yields in patients with multiple myeloma mobilized with intermediate dose cyclophosphamide plus rhG-CSF | Authors: | Hacıoglu, Sibel Sarı, Hakan İsmail Dogu, M.H. Keskin, Ali |
Keywords: | Cyclophosphamide Granulocyte colony stimulating factor Multiple myeloma Stem cell mobilization antineoplastic agent cyclophosphamide mesna recombinant granulocyte colony stimulating factor CD34 antigen granulocyte colony stimulating factor recombinant protein adult aged apheresis article cancer chemotherapy cancer radiotherapy chronotherapy clinical article drug dose increase female hemorrhagic cystitis human male middle aged multiple myeloma peripheral blood stem cell retrospective study stem cell mobilization cost benefit analysis economics metabolism procedures time Adult Aged Antigens, CD34 Blood Component Removal Cost-Benefit Analysis Female Granulocyte Colony-Stimulating Factor Hematopoietic Stem Cell Mobilization Humans Male Middle Aged Multiple Myeloma Recombinant Proteins Retrospective Studies Time Factors |
Publisher: | Elsevier Ltd | Abstract: | Cyclophosphamide along with recombinant human granulocyte-colony stimulating factor (rhG-CSF) is a commonly used strategy for mobilization. However, the optimal timing for rhG-CSF initiation after cyclophosphamide has not been determined as conclusively as has the G-CSF dose. In this paper, we aimed to present gradual dose increment of rhG-CSF between the third day of mobilization and time to apheresis that is started with 5µg/kg (from day 3 to day 7) and continued with 10µg/kg (from day 8 to time to apheresis) for peripheral blood stem cell (PBSC) mobilization in multiple myeloma (MM) patients and its effect on stem cell yield and mobilization success. Data from 30 consecutive patients with MM who underwent PBSC mobilization between October 2011 and June 2013, were retrospectively reviewed. While twenty-eight of 30 patients (93.3%) were successfully mobilized, 2 patients (6.7%) had mobilization failure. The final median CD34+ cell dose harvested from the patients was 9.5×106/kg. The median number of apheresis was 2.5 (range, 0-3). Twenty-four patients (80%) yielded >2×106 CD34+ cells/kg in one apheresis procedure. In conclusion, our regimen might be used to decrease the mobilization failure regarding the low dose rhG-CSF use and provide a cost effective strategy. © 2013 Elsevier Ltd. | URI: | https://hdl.handle.net/11499/7577 https://doi.org/10.1016/j.transci.2013.11.003 |
ISSN: | 1473-0502 |
Appears in Collections: | PubMed İndeksli Yayınlar Koleksiyonu / PubMed Indexed Publications Collection Scopus İndeksli Yayınlar Koleksiyonu / Scopus Indexed Publications Collection Tıp Fakültesi Koleksiyonu WoS İndeksli Yayınlar Koleksiyonu / WoS Indexed Publications Collection |
Show full item record
CORE Recommender
SCOPUSTM
Citations
2
checked on Dec 14, 2024
Page view(s)
68
checked on Aug 24, 2024
Google ScholarTM
Check
Altmetric
Items in GCRIS Repository are protected by copyright, with all rights reserved, unless otherwise indicated.